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The term idiopathic reactive hypoglycaemia (IRH) applies when a meal-induced dip in blood 
glucose, or symptoms of hypoglycaemia, follows high-starch, low-fibre meals in otherwise healthy 
individuals. Due to inconsistency of its definition and debated clinical value, reported prevalence 
of this state varies. No consensus exists on optimal treatment of IRH, hence we wanted to 
investigate 1) the prevalence and characteristics of IRH, and 2) if diet supplementation of fibre 
could improve the reactive glucose response in IRH.  
METHODS:  
362 subjects (71 + 9 years, 146 females), all previously undiagnosed of dysglycaemia, who had 
participated in on of two case-control studies involving a oral glucose tolerance test (OGTT), were 
classified according to WHO standards (type 2 diabetes mellitus (T2DM), impaired glucose 
tolerance (IGT), normoglycaemia (NGT)) or categorized as IRH if OGTT 1h- or 2h- capillary 
blood glucose (cBG) levels were ≤ 3.9 mmol/L or 1h- or 2h- glucose were < fasting cBG, with no 
evidence of T2DM or IGT. Characteristics of the IRH group were aligned with T2DM, IGT and 
NGT groups through a case-control evaluation of lipids, inflammatory- and IGF system 
parameters, cardiovascular complications, medications and anthropometric measures.  
  Further, twelve (56 + 8 years, 6 females) subjects from the IRH minority were recruited in 
a 4-week, randomized, crossover intervention, to evaluate the glucometabolic and anthropometric 
effects of fructo-oligosaccharides (FOS), a dietary soluble fibre with texturising properties (10g 
bid for 2 weeks, no treatment the following 2 weeks). At the end of each 2-week treatment 
sequence, fasting laboratory samples, a 4h-OGTT (blood glucose (BG) measures every 30th 
minute) and anthropometric measures were conducted.  
RESULTS:  
IRH was found in 12.4% of the subjects whom characteristics were: younger, a more favourable 
inflammatory- and IGF system axis profile and lower coronary artery disease (CAD) prevalence, 
compared to all other groups. 
  FOS leveraged a significant improvement in several of the glucometabolic parameters. 
Although some fasting parameters were significantly reduced (plasma glucose and total cholesterol 
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levels; 5.4 + 0.6 vs. 5.1 + 0.5 mmol/L, p < 0.05 and 5.3 + 1.1 vs. 4.9 + 1.1 mmol/L, p < 0.04, 
respectively), most benefits were seen in the 4h OGTT trajectory during the last two hours of the 
4h-OGTT. FOS significantly reduced glycaemic exposure (AUC) between 180 and 210 minutes (p 
= 0.03) and reduced the proportion of capillary blood glucose measurements < 3.9 mmol/L from 
21 to 11(χ2 = 4.26, p = 0.04) in this period. Moreover, favorable alternations in the shape of the 
OGTT curve were seen, with less pronounced zeniths and nadirs.  
CONCLUSION:  
A reactive hypoglycaemic response during an OGTT is prevalent in older adults and this 
phenomenon could be modulated by dietary supplementation of FOS. The stabilizing effects of 
fructo-oligosaccharides on blood glucose should be assessed in patient groups where BG 





















TEORI:   
Idiopatisk reaktiv hypoglykemi (IRH) beskriver tilstanden der inntak av matvarer med mye 
stivelse og lavt fiberinnhold, hos ellers friske personer, fører til et fall i glukosekonsentrasjonen, 
eller symptomer på hypoglykemi oppstår. Definisjonen av IRH og den kliniske viktigheten er 
debattert, det er heller ingen enighet om optimal behandling. Vi ville derfor studere 1) prevalensen 
og karakteristika ved IRH, og 2) om tilskudd av fiber kunne forbedre den reaktive 
glukoseresponsen som ses ved IRH..  
METODER:   
362 personer (71 + 9 år, 146 kvinner), der ingen hadde diagnostisert dysglykemi og som hadde 
deltatt i en av to case-kontrollstudier hvor oral glukosetoleransetest (OGTT) inngikk, ble 
klassifisert i henhold til WHO-standard (type 2 diabetes mellitus, nedsatt glukosetoleranse (IGT), 
normal glukosetolerant (NGT) eller kategorisert med IRH (1- eller 2-timers glukosenivå < 3.9 
mmol/L eller 1- eller 2-timers glukose < fastende glukose med fravær av T2DM eller IGT). I en 
case-kontrollanalyse av lipider, inflammatoriske- og IGF akse-parametere, kardiovaskulære 
komplikasjoner, medikamenter og antropometriske verdier, ble IRH-gruppen sammenliknet med 
personer med T2DM, IGT og NGT . 
  Videre ble tolv personer (56 + 8 år, 6 kvinner) fra gruppen klassifisert med IRH rekruttert 
til en 2-ganger-2 ukers, randomisert crossover intervensjon for å evaluere 20 g/dag frukto-
oligosakkarider (FOS) sin effekt på glykometabolske- og antropometriske verdier. Fastende 
blodprøver, 4-timers OGTT (med kapillære glukosemålinger hvert 30. minutt) og antropometriske 
målinger ble gjennomført avslutningsvis i hver 2-ukers periode.   
RESULTATER:   
IRH ble funnet hos 12.4% av deltagerne, som også var yngre, hadde en gunstigere inflammatorisk- 
og IGF system akseprofil og en lavere forekomst av koronar arteriesykdom (CAD), sammenliknet 
med de andre gruppene.   
  Inntak av FOS førte til en signifikant forbedring av flere glykometabolske parametere. 
Fastende plasmaglukose og totalkolesterol ble signifikant redusert (henholdsvis 5,4 + 0,6 mot 5,1 + 
0,5 mmol/L, p < 0,05 og 5,3 + 1,1 mot 4,9 + 1,1 mmol/L, p < 0,04), og under de to siste timene av 
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4-timers OGTT, observerte vi et signifikant redusert glukoseareal under kurven (AUC) mellom 
180 og 210 minutter (p = 0,03) og et signifikant redusert antall kapillære glukosemålinger < 3,9 
mmol/L fra 21 til 11 (χ2 = 4,26, p = 0,04). Samlet sett ble OGTT-kurven mer utflatet etter FOS-
inntak når senit- og nadir-nivåer ble sammenlignet mot perioden uten FOS.  
KONKLUSJON:  
En reaktiv hypoglykemisk respons under OGTT forekommer i eldre voksne og FOS-
supplementering kan i slike tilfeller være gunstig. Den blodsukkerstabiliserende effekten av FOS 
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Blood glucose (BG) values below lower levels of normal defines hypoglycaemia and in subjects 
with diabetes mellitus (DM) who receives glucose-lowering drugs, this cut-off, according to the 
American Diabetes Association, is ≤ 3.9 mmol/L (1). In subjects without DM however, the 
hypoglycaemia cut-off value is not generally agreed as indicated with proposals ranging from < 2.5 
mmol/L (2) to 3.9 mmol/L (3). This may be due to that the level of glycaemic thresholds for 
secretion of counterregulatory hormones and onset of physiological, symptomatic, and cognitive 
changes in response to hypoglycaemia in non-diabetic humans, is not uniformly reported, and may 
be dependent on setting of which this is measured (2). Furthermore, the diversity of the conditions, 
with their different aetiology, that are known to cause such (Table 1) also could contribute to this 
lack of consensus (5).  
 
1.1 Idiopathic reactive hypoglycaemia (IRH) 
One specific hypoglycaemic phenomenon is the so-called reactive hypoglycaemia (RH), which is a 
time-related and meal-induced syndrome that is characterized by the Whipple’s triad (i.e. 1: 
Symptoms, signs, or both consistent with hypoglycaemia, 2: A low plasma glucose concentration, 
3: Resolution of symptoms or signs with raised plasma glucose) (2). Classically this manifest in 
patients that have submit to gastric (dumping phenomenon) or bariatric surgery (interferes with 
incretin hormones) (6). However, in the case of RH, in apparently healthy individuals experience 
to five hours subsequent to high starch – low fibre meals, with an overall high glycaemic load 
(GL), in the absence of DM or known disease conditions in which this is known to be associated 
with (Table 1), and without fulfilment of the Whipple’s triad, this is termed idiopathic reactive 
hypoglycaemia (IRH) or idiopathic postprandial syndrome (7).  
 The definition of IRH is not agreed. It was originally described by Harris who suggested in 
1924 this condition to relate to postprandial glucose values < 4.0 mmol/L (8). Brun et al. (6) later 
suggested a cut-off of < 3.3 mmol/L, while Marks & Teale, rather than relating cut-off values to 
meal, defined IRH to plasma glucose levels of less than 3 mmol/L during the standard oral glucose 
tolerance test (OGTT) (9).  
 IRH is by some not regarded as a disease entity (10, 11), which might be related to absent 
symptoms corresponding with biochemical hypoglycaemia (12). However, the prerequisite in 
literature for BG to be  3.3 mmol/L during symptoms for to classify IRH may be too limited since 
after consumption of a high glycaemic-index breakfast individuals prone to IRH have reported 
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symptoms at higher BG level (4.40 + 0.83 mmol/L) than traditional threshold values (13) and 
several studies shows that symptoms of hypoglycaemia do not correspond to measured plasma 
glucose (14, 15). Three studies, from UK, Canada and Denmark, e.g. found that only 23%, 47% 
and 0%, respectively, of study subjects had plasma glucose values ≤ 3.3 mmol/L and 
simultaneously symptoms of hypoglycaemia (16-18).  
  Moreover, study subjects are usually semisupine during protocols used to investigate 
symptom thresholds, whereas it has been shown that symptoms and physiologic responses to 
insulin-induced hypoglycaemia are increased when upright (19), therefore, symptom thresholds, 
defined by hyperinsulinemic clamp studies, may underestimate hypoglycaemia in free-living, 
ambulatory individuals. 
 
1.2 Prevalence of IRH             
The reported prevalence of IRH varies due to non-agreement in the diagnostic practice and the 
difficulty in identifying the aetiology and the fact that probably the majority of subjects reporting 
this problem do not have a biochemical hypoglycaemia after conventionally comprehensions/ 
appraisals (20). In a British trial among 1136 randomly chosen women aged 17-50 years, self-
reported symptomatic hypoglycaemia occurred among 37.9% four times monthly (21). In selected 
populations it may even be higher, as a prevalence of 30 and 50% is reported in type 2 DM 
(T2DM) and in lean, young women with polycystic ovary syndrome, respectively (22, 23). This 
indicates that a substantial number of subjects are affected by IRH, and from lessons learned from 
hypoglycaemia occurring in DM (24), this might have a deleterious impact on health-related 
quality of life (HRQL) (25).  
 Postprandial hypoglycaemia has been popularized in the media and lay literature and in 
several countries the number of persons being referred for medical assessment of this condition is 
high (10, 21). The syndrome is alleged to be more prevalent among lean people with a low fat 
percent (6, 21), possibly due to that slimming increases insulin sensitivity (26) and that during 
increased glucose processing by exercise, there is frequently observed cases of exaggerated 
decrease in blood glucose. Such antecedent hypoglycaemia during the preceding day can blunt 
neuroendocrine glucagon, insulin and catecholamine responses as well as endogenous glucose 
production, lipolysis and ketogenesis and by this, impairing defences against exercise 
hypoglycaemia (27).  
 It has also been noted a higher prevalence of IRH in women, possibly due to the sexual 
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dimorphism in counterregulatory responses to hypoglycaemia where plasma glucose values would 
have to fall to a lower level in women before release of counteracting hormones take place 
compared to in men (28) with a 44% and 17% lower epinephrine and norepinephrine response, 
respectively (29) and a twofold greater glucagon response in men relative to women (30). This was 
also seen in a study examining the shape of the curve during an OGTT (31), where biphasic curves 
was observed more frequently and more pronounced in women than in men. The latter study found 
genetic variations to be involved too, where homozygosity of the cysteine protease calpain 10 
(CAPN10 UCSNP44) allele was associated with a monophasic shape.  
 
1.3 Bio-pathological explanation for IRH 
Although there are several symptoms due to hypoglycaemia, the most frequently observed can be 
grouped as either autonomic (i.e., sweating, warmth sensation, anxiety, nausea, palpitation and 
hunger) (32) or related to neuroglucopenia (i.e., tiredness, being uncoordinated, visual 
disturbances, drowsiness, altered behaviour, confusion, and, if left untreated, coma and seizures), 
caused by glucopenia in the brain (33).  The autonomic symptoms tend to occur first, at a blood 
glucose level of around 3.3–3.6 mmol/L and neuroglucopenia at lower levels, e.g. < 2.6 mmol/L 
(20). Hence, glycaemic thresholds for activation of an autonomic endocrine response are higher 
than those for the development of symptoms and impairment of cognitive function (6). The 
classical hierarchy for this in subjects without diabetes is illustrated in Figure 1.  
 To maintain glucose homeostasis the body requires mechanisms to respond to the 
intermittent provision of nutrients and intervals of no nutrient supply. In healthy persons 
postabsorptive euglycaemia is regulated within approximately 3.3 to 5.6 mmol/L despite 
intermittent ingestion of food (34). Insulin is the chief modulator of keeping this balance, and its 
secretion from pancreatic islet β-cells is stimulated by enteric incretins following ingestion of 
nutrients. In the postabsorptive state glucagon secreted from the pancreatic islet α-cells stimulates 
glucose production and provides the primary defence against hypoglycaemia, but has no effect on 
extrahepatic glucose uptake (35). In the absence of glucagon, adrenomedullary epinephrine and the 
10 times less potent norepinephrine, has an important role in the counterregulation by decreasing 
glucose utilization, increasing glucose production and reduce insulin secretion (36). Cortisol, on 
the other hand, is needed for normal glycogen synthesis and for the acceleration of glucose 
production by glucagon and epinephrine (6) and increments in plasma cortisol levels is seen in the 
late or profound hypoglycaemic phase together with increased secretion of growth hormone (19).  
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 Irregularities in these hormonal- and/or cerebral mechanisms that otherwise tightly control 
the complex interplay of mechanisms involved in regulating BG level are one of the causations of 
IRH. This involves e.g., decreased or increased insulin secretion and/or defects in 
counterregulatory hormonal response (glucagon, epinephrine, norepinephrine, cortisol or growth 
hormone) (37) whether this affects secretion or receptor hypersensitivity (26). Basal glucagon is 
correspondingly reported to be significantly higher in subjects with IRH compared with normal 
subjects. During a 3-hours OGTT a paradox increase in plasma glucagon was noted in the IRH 
individuals together with a significantly delayed insulin peak, which might indicate an altered 
pancreatic α-cell function in these patients (35).      
  This is not the complete explanation though, because glucagon does not cause symptoms 
(but epinephrine does). The postprandial adrenergic response appearing after meals rich in 
carbohydrates and the rare association with low blood glucose level, could therefore be a result of 
higher beta-adrenergic sensitivity (17) or an earlier secretion of epinephrine in response to a falling 
blood glucose as has been reported in non-insulin treated T2DM patients (38). 
 Also involved could be disturbances in the entero-insular response with increased 
glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (39). 
GLP-1 is secreted from the terminal ileum and colon L cells in reply to nutrients in the gut and is 
one of the most potent insulin stimulants (40). Although GLP-1 receptors are widespread in the 
body, in this context the gastric, hepatic and pancreatic ones are of most interest. This incretin 
inhibits gastric emptying and postprandial glucagon release (41), thus decreasing hepatic glucose 
production (1). GIP is secreted from K cells primary in the proximal small intestine. The GIP 
receptor is expressed in the pancreatic islet cells, adipose tissue, heart, pituary, adrenal cortex and 
several regions of the brain (42). As with GLP-1, this incretin stimulates insulin secretion and its 
secretion increases 10- to 20-fold above baseline values within minutes of ingestion of absorbable 
carbohydrates as well as lipids (40). Nauck and colleagues noted that approximately 50-70% of the 
insulin response to an OGTT can be attributed to the effect of incretins on the islet β-cells (39). 
Individuals with T2DM exhibit impairments in both GLP-1 and GIP secretion as compared to 
healthy individuals (43). Their impact on inducing hypoglycaemia however is limited, since they 
only exert an insulin-secretory stimulus in the presence of hyperglycaemia (44). However, since 
most cases of symptoms in IRH are in subjects without a biochemical low value, disturbances in 
this system also could play a role (45).  
 Notwithstanding, the most plausible explanation of IRH is probably attributed to high 
insulin sensitivity that is not adequately compensated by hypoinsulinemia (23). Hence with an 
endogenous hyperinsulinaemia, at least in relative terms, the dysfunction lies in the failure of 
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insulin to fall to very low rates as plasma glucose concentrations fall to hypoglycaemic levels, with 
the result of low rates of glucose production rather than high rates of glucose utilization (33). This 
is reflected in studies addressing the shape of the OGTT curve where a biphasic pattern with 
accentuated zeniths and nadirs seem to be present in subjects with IRH-like conditions (Figure 2) 
(31).  
 Interestingly, the shape of the glucose curve during OGTT may harbour metabolic 
information not captured by the level of glucose at present, e.g. glucagon secretion and sensitivity 
and hepatic glucose sensitivity. The shape of the BG curve has been categorized as ‘monophasic’, 
biphasic’ or  ‘unclassified’ (31) or ‘domed’ and ‘upward’ (46). Both insulin sensitivity and insulin 
secretion are involved as well as gastric emptying in the physiological processes contributing to 
the shape of the slope of the initial rise. Opposing this, OGTT features a non-physiological stress 
situation seldom encountered outside the clinical laboratory and induces a somewhat different 
glucose kinetic than a mixed meal (31) witch could give rise to false positive results (47). Instead it 
has been proposed to use a questionnaire (36), a classification of symptoms with a multifactorial 
analysis (48) or a breakfast test that mimics everyday habits and rules out artefacts as for the 
OGTT (49). By contrast, it is suggested that OGTT could still be employed for further 
investigation of relationships between symptoms and blood glucose values and in evaluation of 
glucose tolerance after the diagnosis has been made (48).  
  Conventional home blood glucose monitoring provides only a snapshot picture of 
prevailing glucose values and the gold standard seems to be ambulatory glycaemic measurements 
(6). The rationale for the use of this device is to detect unrecognised hypoglycaemia, especially at 
times when finger prick testing is difficult or impossible (e.g. at night). Subcutaneous glucose 
levels mimic blood glucose levels closely with a lag time of only a few minutes (50, 51). An 
investigation of 29 patients referred for a suspicion of a hypoglycaemic disorder with continuous 
glucose monitoring system (CGSM), found 46% of the symptoms to occur when BG < 3.3 mmol 
and 18% < 2.8 mmol (17). Since symptoms are not specific and OGTT is suggested not helpful in 
diagnosing IRH, frequent glucose measurements allows a personalized and more precise 
understanding of daily glucose fluctuations, giving the time and glucose levels followed by 
symptoms (52). Identification of glucose oscillations have been suggested to be a more reliable 
indicator of blood glucose control and risk for long-term complications than HbA1c alone (53), 
further are plasma insulin, GLP-1 and GIP responses found to be greater when a variable infusion 
of glucose is given, as is more representative for the situation in daily life, compared with a 
constant infusion in both healthy and T2DM patients (54). 
 18
1.4 Treatment of IRH 
No specific recommendations for treatment have been proposed but in general, meal-related 
reactive hypoglycaemia should primarily be treated with dietary restriction of refined 
carbohydrates (55), frequent meals, and avoiding coffee and nicotine, although much controversy 
exists as to the optimal management of reactive hypoglycaemia (35, 49). Pharmacologic attempts 
in treating IRH involve potassium-channel activators (diazoxide) (6), biguanides (metformin) (56), 
α-glucosidase inhibitors (57), calcium-channel blockers, anticholinergic agents, phenformin (no 
longer widely available) (58), thiazolidinediones (glitazones), and somatostatin analogues (59). 
However, none of these medications are specifically indicated (60) and their long-term use in this 
indication has not been firmly established in controlled studies (61).  
 
1.5 The potential impact of fibre on IRH 
In people with frequent blood glucose variations, increased fibre intake for 24h is associated with a 
reduced postprandial glucose response on the following day (62). In fact, supplementing 
carbohydrate test meals with purified fibre has been shown to flatten the glycaemic response in 
healthy volunteers (63), to reduce urinary glucose loss, accelerate acute GIP- and insulin response 
(62) and improve diabetes control in subjects with DM (64). Involved in these advents may be the 
fermentation remnant and short-chain fatty acid (SCFA) acetate, that is capable of inhibit serum 
free fatty acid release from adipocytes (65), resulting in increased insulin sensitivity (64). Fibre 
also plays an important role in preventing T2DM (66) and reduce cardiovascular disease (CVD) 
risk and CRP levels (67,68). Longitudinal studies indicate an inverse association between dietary 
fibre intake and levels of inflammatory markers (69) such as interleukins (IL)-6, tumour necrosis 
factor alpha receptor-2 (TNF α-2R) (70) and CRP (69). IL-6 is probably the chief stimulant to 
hepatic production of CRP (71) and modulation of the cytokine milieu is possible with increasing 
the fibre content in meals (72), independently of body weight change (73). This is further 
emphasized when insulin, GIP, and GLP-1 responses to whole kernel rye bread is lower compared 
to consumption of white wheat bread (74). Dietary fibre may therefore play an important role in 
mediating the relation between diet, inflammation and cardiovascular disease (75) by way of 
altering the intraluminal bacterial environment witch contributes in the production of inflammatory 
cytokines (76).  
  A meta-analysis of 67 controlled trials that evaluated the role of dietary fibre on serum 
cholesterol indicated that high-carbohydrate diets, rich in soluble fibre (from oats, psyllium, pectin, 
and guar gum) decreases total- and low-density lipoprotein (LDL) cholesterol, with insignificant 
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effects on triglycerides and high density lipoprotein (HDL) cholesterol (77). Also, the fermentation 
products of fibres (including acetate) have shown to induce apoptosis of colorectal cancer cells 
(78), maintain mucosal respiration and growth (79) and synthesize folic acid, biotin and vitamin K 
(80).  
  Despite these only assorted mentioned mechanisms through which fibre in general can 
assist healthiness, the total consumption among the Norwegian population is far lower than the 
recommended 25 - 35 g/day (81, 82) with an estimated intake between 16 to18g/day (83). In other 
western societies consumption is even smaller (84), as for US with only 15 g/day (85).  
 
1.6 Oligofructose 
Inulin and oligofructose are linear β2-1 fructans (63) present in several fruits and vegetables 
(wheat, onion, banana, garlic, Jerusalem artichokes and chicory) (86) and their daily consumption 
has been estimated to 1-4g in the US (87) and 3-11g in Europe (86). Fructo-oligosaccharides 
(FOS) is made from chicory inulin which is enzymatically hydrolyzed to yield a degree of 
polymerization between 3 to 5 (Figure 3) (79). Oligofructose is resistant to hydrolysis by human 
small intestinal digestive enzymes, whereas being fermented by only a limited range of micro 
organisms in the proximal colon including the valuable, health promoting species bacteroides and 
bifidobacteria (88). Contrary, the concentration of fusobacteria and clostridia is suppressed (89), 
insinuating FOS to meet the criteria to be considered a prebiotic defined as: A non digestible food 
ingredient that selectively stimulates growth and/or activity of one or a limited number of colonic 
bacteria, and thus beneficially improves host health (89). Unlike the situation with probiotics, 
where allochthonous micro organisms are being introduced in the gut, and have to compete against 
established colonic communities, an advantage of using prebiotics to modify gut function is that 
the target bacteria are already commensally in various extents, to the large intestine. Thus, 
prebiotic supplementation seems to play a more important role in older individuals, e.g.  > 55 years 
where faecal bifidobacterial counts are known to show marked decrease in comparison to those of 
younger persons (90) 
  By delaying gastric emptying (bulking effect) and retard nutrient absorption by trapping of 
low molecular weight carbohydrates in a viscous gel (89), oligofructose, together with a possible 
enhanced glucose utilization from colonic fermentation products of the fibre (47), could improve 
postprandial misbalance in the secretion of insulin and glucagon (91, 92).  
  A potential use of FOS in particular in IRH is supported by a 4 week study of 20g FOS/day 
or sucrose in 12 healthy volunteers that showed decreased basal hepatic glucose production after 
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FOS (P < 0.02) and an acetate-propionate ratio two times lower compared to lactulose in the 
volunteers faecal inoculums (91). This improved metabolism was related to the gluconeogenerator 
propionate, witch has been shown to inhibit gluconeogenesis from lactate and to stimulate 
glucolysis (92). Moreover, a crossover study with 30 subjects reported that intake of 10.6g/day of 
FOS in 2 months gave a significantly reduced postprandial insulin response (incremental area) 
after a standard test meal (protein 15%, carbohydrate 34%, fat 51%). On the other hand, the 
authors did not find any major effects on lipid metabolism (93) as seen in experimental models 
with rats, where FOS has been implied to lessen hepatic steatosis (94), presumably related to the 
dose-dependent response of functional fibres (95).  
  As in line with fibre in general, FOS also has been reported to reduce the risk of colon 
carcinogenesis, improve the bioavailability of essential minerals (magnesium and calcium) and 
reduce serum triglyceridemia by lowering hepatic lipogenesis (96).  
 
1.7 Aims of the study 
IRH, despite its limitations as possible not being a disease entity, is a condition probably highly 
prevalent in the population. We therefore wanted to investigate its prevalence and associated 
characteristics and to conduct a trial to explore the possible benefits of daily FOS-supplementation 
on BG stability in IRH. Primary aims: 
1) To study the prevalence of IRH, in older Caucasian subjects who previously had 
participated in studies investigating the prevalence of undiagnosed hyperglycaemia, and through a 
case-control design explore its characteristics as compared with subjects with hyperglycaemic 
(T2DM or IGT) or normoglycaemic responses during an OGTT. 
2) To evaluate, in a randomized crossover trial, the effect of FOS supplementation on 




This study, that was conducted at the Asker and Baerum Hospital, a secondary referral hospital in 
Southern Norway serving a population of approximately 150000, investigated the prevalence of 
IRH in subjects without a previous diagnose of diabetes or pre-diabetes, and compared 
anthropometric measurements, blood sample measurements, medication use, and cardiovascular 
(CV) complications and CV risk factors in subjects with type 2 DM (T2DM), impaired glucose 
tolerance (IGT) or those being normoglycaemic (NGT). This was done by a pooled analysis of the 
databases from two case-control studies; the Asker and Baerum Atrial Fibrillation study (n=152) 
(97) and the Glucose ABnormalities in Ischemic conditions study (n=210) (98). In short, these 
studies showed a high prevalence of undiagnosed abnormal glucose metabolism (> 50%) in 
patients with either long-standing atrial fibrillation (≥ 5 years) or CV complication, irrespective of 
vascular bed involved. 
 In addition, through an exploratory pilot trial (ClinicalTrial Gov. Id.: NCT00802971) we 
assessed the impact of oligofructose on reactive hypoglycaemia and parameters of 
glucometabolism in subjects with IRH, recruited from the two cohorts above, in a randomized, 4 
weeks, crossover, pilot trial (FOS study). The protocol was approved by the Regional Committee 
for Medical Research Ethics, Norway and by the Norwegian Data Inspectorate. Each subject gave 
informed written consent before participating in the study that was conducted according to the 
Helsinki declaration. No compensation was given. 
 
2.1 Classification of dysglycaemia, definition of IRH and assessment of glucometabolic parameters 
An OGTT with ingestion of 75g glucose dissolved in 300ml water flavoured with citric acid was 
performed according to WHO standards, but with the supplement of a 1hour (h)-glucose 
measurement in all study participators. Blood glucose during the OGTT was analyzed immediately 
in capillary whole blood (photometer; HemoCue, Ängelholm, Sweden). The OGTT results were 
classified as 1) IRH if 1h- or 2h- glucose levels ≤ 3.9 mmol/L or if 1h- or 2h- glucose levels were 
< fasting glucose (fBG) (and no evidence of T2DM or IGT), 2) T2DM (fBG > 6.1 mmol/L or 2h 
BG ≥ 11.1 mmol/L), 3) IGT (fBG < 6.1 mmol/L and 2h BG [7.8 – 11.1) mmol/L) or 4) NGT (fBG 
< 6.1 mmol/L and 2h BG < 7.8 mmol/L). The three latter was classified according to criteria of the 
World Health Organization (WHO) (117).  
   Insulin was analyzed by radioimmunoassay using an antibody with no cross-reaction 
against pro-insulin (Diagnostic System Laboratories, Webster, TX). The homeostasis model 
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assessment for insulin resistance (HOMA-IR) was calculated in fasting conditions as plasma 
insulin (pmol/l) x blood glucose (mmol/L) / 135. 
  Glucagon was assessed by competitive radio immunoassay (Millipore Corporation, 
Billarica, Ma, US). HbA1c was analysed by colorimetric and immunoturbidimetrical methods in 
whole blood with an upper normal limit reference value of 6.1%. Serum levels of total cholesterol, 
high-density lipoprotein (HDL)-cholesterol, triglycerides (TG) and glucose were measured 
enzymatically, all using on a Cobas Integra 800 (Roche Diagnostics, Rotkreuz, Schweiz). Low-
density lipoprotein (LDL)-cholesterol was calculated using Friedewald’s formula. 
 Handling and analysis of the inflammatory parameters are previously described (97, 98). 
 
2.2 FOS study – objectives 
When screening for eligibility from the crossover intervention, all subjects with IGT or DM2 
where excluded. Key variable was the registered hypoglycaemia during 2h OGTT as defined 
earlier.   
 Twelve subjects diagnosed with IRH who previously had participated in on of the two case-
control studies, were recruited by written invitation to participate in a four-week, parallel-group, 
crossover, open randomized intervention study comparing no treatment vs. fructo-oligosaccharide 
(F.O.S., BioCare Ltd. Birmingham, Great Britain) supplement. Patients were only included if they 
fulfilled the above IRH criterions but were excluded in the case of liver disease, insulinoma, 
gastrointestinal disease history, previously bariatric surgery or having the potential to become 
pregnant. 
  Primary objective was to evaluate FOS’ effect on reactive hypo- and hyperglycaemia 
associated with IRH assessed by a 4-h OGTT. Secondary objectives were to evaluate impact of 
FOS on lipids, glucometabolic and anthropometric values and change in the 24h interstitial glucose 
AUC assessed by CGSM. 
 
2.3 Crossover study details 
Baseline procedures included fasting blood sampling and analysis (fasting blood glucose, HbA1c, 
lipids, HDL- and LDL-cholesterol, total cholesterol, triacylglycerol, insulin, glucagon, creatinine, 
CRP), measurement of anthropometric measures (weight and height), resting supine blood pressure 
(Omron, M6 Comfort, Omron Healthcare Co., Ltd. Kyoto, Japan) and questionnaires (intake of 
dietary fiber, frequency of meals, evidence of symptoms or signs of hypoglycemic episodes, use of  
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medication, leisure time physical activity and smoking, Appendix c). 
  In the first two weeks of the study, half of the participators were randomized to twice-daily 
FOS supplementation (2 x 10g) provided as powder in sealed bags to be dissolved in tap water and 
drunk within 20 minutes prior to breakfast and dinner. The resting half received no treatment. At 
day 12, all participators were advised to follow a written, pre-defined, food plan for 40 hours (1800 
kcal/24 h for women and 2200 kcal/24 h for men, Appendix A and B, respectively). At day 13, all 
participators came to the hospital for registration with CGMS (CGMS Minimed®, CA, US or 
Medtronic Guardian RT Minimed, CA, US) to be used for 24 hours. At day 14 the participators 
came, in fasting state, to the hospital between 8 – 10a.m. for venous blood sampling (haemology, 
lipids and hormones), a 4h OGTT and detachment of the CGMS system. The following two weeks, 
these assessments were repeated for both groups, but then respectively without, and with, twice-
daily FOS supplementation (crossover study). 
 All participators received a glucose meter (Freestyle Lite, Abbott) for capillary blood 
glucose measurements and a diary for reporting hypoglycemic symptoms (e.g. nausea, tremor, 
coldness, hunger, aggressiveness, or headaches) during the duration of the study. All participators 
also performed a 7-point blood glucose (at 8a.m., 10a.m., 12p.m., 14p.m., 17p.m., 830p.m., 
1130p.m.) profile during the period of the CGMS registrations. During the 4-week period, subjects 
were also asked to grade any hypoglycaemic symptoms from the least to the most bothersome (0-
10). Adverse events, whether related to fiber or not (e.g. abdominal pain, eructation, distension, 
borborygmi, flatulence, bloating, and diarrhea) were registered in the same diary.  
 
2.4 Statistical analysis and sample size calculation 
Sample size calculation for the exploratory pilot trial where based on a study in 13 subjects with 
T2DM where 24h plasma glucose levels was reduced by 10% during fibre supplementation (100). 
Hence we expected that 50% of participators with IRH receiving FOS would experience a blood 
glucose stabilizing effect as defined by no longer fulfilling 2h OGTT IRH definition as compared 
to 10% among those not receiving FOS. Our null hypothesis was that there should be no difference 
with regards to the impact of FOS on these criteria, and as we wanted a statistical power of 80% 
and an alpha error level of 5%, we needed 15 individuals in total. To account for drop-out we 
therefore decided to include 16 subjects.  
  Data analysis was performed using SPSS statistical software version 17.0.1 for Windows 
(SPSS Inc., Illinois, US). Results for continuous variables are presented as means and respective 
standard deviations as well as minimum and maximum values, unless otherwise stated. Between-
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group statistical analysis of continuous parameters was examined for statistical significance with 
student’s t-test for two independent samples in the case control study and in the randomised 
crossover trial the two pairs of continuous parameters were assessed with paired students t-test 
(normal distributed data) or Wilcoxon Signed Ranks test (non-normal distribution). Correlation 
coefficients are univariate derived using Spearman’s correlation. Categorical variables are 
presented as counts or proportions (%) and statistical comparisons of these parameters were carried 




















3.  RESULTS  
 
3.1  Prevalence of IRH 
The ABAF and GABI study population consisted of a total of 362 subjects (146 females [40.3%]), 
aged 45 – 87 (mean + SD 71 + 9) years, all without previously known DM, of whom 215 (59.4%) 
had a prior CV complication (i.e. coronary artery disease, cerebrovascular disease or peripheral 
occlusive arterial disease) and 30 (19.5%) atrial fibrillation.  
All subjects performed a capillary 2h OGTT with the ingestion of 75g glucose, according to 
WHO standards. The OGTT revealed that 42 (11.6 %) of the subjects had undiagnosed type 2 DM 
(T2DM) (fasting capillary blood glucose [fcBG] > 6.1 mmol/L or 2h-cBG > 11.1 mmol/L), 
whereas a non-diabetic hyperglycaemic reactive response was found in 71 (19.6 %), i.e. impaired 
glucose tolerance (IGT [fcBG concentration < 6.1 and 2h-cBG 7.8 - 11.0 mmol/L]) and a 
hypoglycaemic reactive response, defined by IRH (fcBG < 3.9 or 1h- or 2h-cBG < cfBG [T2DM 
and IGT excluded]) in 45 (12.4 %). 204 subjects (56.4%) were considered NGT, although 68 (18.8 
%) of these had impaired fasting glycaemia (IFG) (fcBG 5.6 - 6.1 mmol/L and a 2h-cBG < 7.8 
mmol/L). However, in the further analysis the IFG group is considered as, and comprised amongst 
the NGT group, since these subjects are lacking a pathological reactive glucose response. Figure 4 
indicates the mean glucose values for the different groups.  
 
 
3.2 Characteristics of IRH  
Characteristics according to glucometabolic classifications (T2DM, IGT, IRH, NGT) are given in 
Table 2. Subjects in the IRH group (68 + 10 years) was significantly younger than those in the 
T2DM (73 + 7 years, p = 0.02) and IGT group (74 + 6 years, p < 0.001), but not as compared to 
the NGT group (70 + 9 years, p = 0.06). No between-group difference was seen in BMI or waist- 
or hip circumference. Overall, there was a significant positive correlation between BMI, weight, 
waist circumference and hip circumference with cfBG and 1h-cBG (Table 3), which also tended to 
be the case within each separate group (data not shown).  
Of note was also that the subjects in the IRH group had a lower CAD prevalence vs. the 
other groups, i.e. amongst l1.1% of IRH subjects whereas 23.5% in the NGT group (p=0.06), 
32.4% in the IGT group (p=0.008) and 33.3% in the T2DM group (p=0.009). Correspondingly, 
also, the use of CV drugs (i.e. beta blockers, statins, warfarin, renin-angiotensin system blockers) 
was higher in all other groups (Table 2).  
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Glucometabolic and lipid parameters 
HbA1c, fasting plasma glucose, insulin and HOMA-IR were significantly lower in the IRH group 
as compared to the T2DM group (Table 4). This was true for the 1h- and 2h-cBG values as 
compared to the T2DM and IGT groups as well. As expected, overall HOMA-IR correlated 
significantly positive with fcBG, 1h- and 2h- BG levels, indicated in Table 3. This was also the 
case when each group was analysed separately, although level of significance was not always met 
(data not shown).   
 Lipid values (except TG) were lowest in the T2DM group (Table 4), whom also had the 
highest proportion of statin users (Table 2). However, no differences in lipid values were noted for 
IRH vs. the other groups, despite also here a difference in the proportion of statin treated subjects 
(Table 2).  
 
 
Parameters of inflammation and the IGF system axis 
Inflammatory- and IGF system axis parameters evaluated indicated a more favourable profile in 
the IRH subjects for most parameters. Statistical significance was however only reached against 
the T2DM group (for IL-10, TNFR-1, TGFB-1, IGF-1 and CRP) and in the IGT group (for TNFR-
1, IGF-1 and CRP) (Table 4). 
 In a bivariate overall correlation of these parameters vs. cfBG, 1h- and 2h-cBG, there were 
seen a significant relation against white blood cells, CRP and TNFR-1, and a significant 
correlation between IGFB-3 and IGF-1 and 2h-cBG (Table 3). 
   
 
3.3 Impact on parameters of glycaemia and lipids by dietary supplementation of fructose 
oligosaccharide (FOS).  
Baseline characteristics 
The randomized trial took place between December 2008 and March 2009. Six men and six 
women (mean age 56 + 8 years, BMI 25.0 + 2.9 kg/m2, HbA1c 5.8 + 0.3%) were recruited from 
the IRH group (with mean OGTT results: cfBG, 1h- and 2h-BG of respectively 5.3 + 0.5, 8.4 + 2.2 
and 4.4 + 0.9 mmol/L) as previously described, by written invitation, to participate in a 4-week 
crossover study. Amongst these 12 subjects, two (17%) reported daily symptoms indicating 
hypoglycaemia, while a total of seven (58%) reported to experience sporadic symptoms of 
hypoglycaemia in daily life.  
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In agree with the protocol, the study consisted of two consecutive two-week sequences i.e. 
with and without FOS supplementation administrated twice daily (2 x 10g) taken breakfast and 
dinner.  
According to self-reported inquires, the participants consumed a mean number of five daily 
meals and 2.5 + 1.1 of those meals contained fibrous ingredients (defined as lentils, oatmeal or 
nuts, whole kernel bread, vegetables or fruit).  
Leisure time physical activity was reported to 5.8 + 2.4 hours. 10 (83%) of the participants 
accentuated a healthy diet, in conjunction with the baseline propitious characteristics in Table 5 




Treatment sequence results 
Eight of the 12 participants were randomly (randomization list generated by computer program 
[randomizer.org]) assigned, using sealed envelope kept away from personnel involved in the study, 
to receive FOS supplementation for the initial 2-week sequence. For all 12 subjects, mean days 
with FOS consumption were 16 + 4.5. There were no dropouts. 
 
  
4h OGTT  
At the end of each 2-week sequence a 4h OGTT was conducted with cBG measures every 30 
minutes. In the preceding 36 hours of the OGTT all subjects followed a standardized diet of 1800 
kcal for women and 2100 kcal for men, with a fibre content of 31 and 40g, Appendix a and b, 
respectively. The dietary compliance in these two diet-controlled days was excellent as assessed by 
direct question. 
The results of the 4h OGTT are detailed in Table 7 and Figure 5 and 6 (a-l), the latter 
indicating individual OGTT data of FOS vs. no-FOS. As is evident, the definite effect of FOS is 
assessed by modulation of amplitude (zenith and nadir) and shape of the OGTT curve, where the 
shape index (a measure of glucose variation) improved non-significantly during FOS 
supplementation. All subjects had a biphasic OGTT shape curve with relatively high and early 
zeniths and slow and deeper nadirs (an indication of high glucose variability) before FOS 
supplementation, which was reduced to nine on FOS supplementation.  
The blood glucose stabilizing effect was also noticed by a significant reduced glycaemic 
exposure (AUC) between 180 and 210 minutes in the FOS sequence (Table 7) and a lower 
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proportion of subjects with cBG measurements < 3.9 mmol/L during the last 2 hours of the OGTT 
from 21 to 11 (χ2 = 4.26, p = 0.04, Figure 7). 
 
 
CGMS test results and SMBG 
CGMS registration was deemed successful if a set of 288 measurements/24h were available. Due 
to technical difficulties however, only four of the 12 CGMS-sets were valid. Notably, no 
participant finished premature due to sensor discomfort. Thus; since CGMS registrations were 
available for only 30% of participants, no meaningful analysis of this could be conducted.  
 However, study subjects were also asked to perform SMBG the preceding day of the 4h 
OGTT. These results are displayed in Table 8, indicating a tendency of a mediation of cBG in the 
forenoon hours. 
       
 
Glucometabolic and anthropometric parameters 
Table 9 shows the laboratory assessments following each intervention sequence. Wilcoxon signed-
rank test gave significant reduction in glucose and total cholesterol following FOS sequence (5.4 + 
0.6 mmol/L vs. 5.1 + 0.5 mmol/L, p < 0.05 and 5.3 + 1.1 mmol/L vs. 4.9 + 1.1 mmol/L, p < 0.04, 
respectively) and decrements in white blood cells, weight, insulin and insulin – glucagon ratio, 
notwithstanding they did not reach statistical significance.  
 
 
3.4 Tolerability of FOS supplementation, FOS compliance and hypoglycaemic symptoms  
All subjects enrolled in the present pilot intervention completed the study and ccompliance to FOS 
supplementation was high as assessed by direct questions. Any adverse events reported were of a 
mild to moderate nature and specific to GI discomfort (e.g. flatulence, abdominal distension and 
intestinal rumbling). One participant reported increased and prolonged satiety, another 
improvement in bowel function. The extent of hypoglycaemic symptoms announced did not 
diverse in the two intervention weeks. 





In this study, 10% of subjects in a relatively large and heterogeneous group of older adults reacted 
with a hypoglycaemic response during OGTT according to the proposed criterion of IRH, and two 
weeks diet supplementation with fibre (FOS) gave an overall more advantageous OGTT response 
(zenith, nadir and numbers of episodes of BG < 3.9 mmol/L levels), as well as had a beneficial 
impact on fasting total cholesterol and plasma glucose.  
A prevalence of one in 10 subjects having a reactive hypoglycaemia is in line with studies 
from UK and US (101, 9), whereas others state this to be a rare phenomenon (32, 102). 
Interestingly, in lean, young women with PCOS, a reactive hypoglycaemia was seen in 50% (23).     
 Ever since Harris’ (8) report of hypoglycaemic symptoms at BG values < 3.9 mmol/L, this 
defining limit has fluctuated (2, 3) making it troublesome to evaluate its true prevalence. In 
agreement with this, the abovementioned UK study set the hypoglycaemic threshold to 3.3 mmol/L 
yet Marks & Teale used 3.0 mmol/L (101, 9). Additionally, habitual glucose intervals changes 
according to age, as young, lean, healthy women with plasma glucose levels towards 2.2 mmol/L 
are not unusual (103) whereas in elderly people BG < 3.3 is an independent risk factor for in-
hospital mortality (104). To emphasize this, our study population was pre-selected with a mean age 
of 72, with regard to 27 in Simpson’s study of self applied participants.  
As compared with those with hyperglycaemic reactive- or normoglycaemic responses, the 
IRH subjects were characterized of being younger, having less CV complications and a more 
favourable inflammatory- and glucometabolic profile, which also are previously described 
characteristics (23, 27). Contrary, the present study do not support a suggested higher prevalence 
of IRH in women (16) or in those with lower BMI (6, 21) which in our situation could colligate to 
selection bias.  
  Moderate elevated inflammatory parameters promote cardiovascular degeneration (105). 
Interestingly, when resemble the four groups together, we observed a lower proportion of CV 
complications in the IRH group, they also presented a more beneficial inflammatory and 
glucometabolic profile. Whether there is a link between these characteristics remain to be settled in 
further studies, but if this is the case it could be conflicting with studies showing that low blood 
glucose levels can heighten the level of inflammatory parameters (106). Insulin hypersensitivity 
and defects in gastrointestinal-pancreatic β-cell signalling network as has been reported in IRH 
(107) increase the occurrences of BG < 3.5 mmol/L in witch activates counterregulatory defences 
that will disturb everyday life with marked discomfort and attenuated intellectual or psychomotor 
function. Studies on driving performance also affirm disturbances in several neurological functions 
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at BG levels > 3 mmol/L (108). Moreover, bothersome clinical manifestations and clinical trivial 
events without biochemical hypoglycaemia might have impact on HRQoL (24) and theoretically, a 
low BG may increase food consumption or elaborate physical exercise in fear of symptoms.  
The present investigation showed a beneficial effect of fibre in IRH. Apart from stabilizing 
glucose amplitude and reduce number of cBG measurements < 3.9 mmol/L during the last 2 hours 
of the OGTT, also noticed was a significant flattened glycaemic exposure in the interval 180 – 210 
minutes post glucose load and an improvement in shape index during FOS supplementation. 
Supported by the research of Yamashati et al. and Delzenne et al. (109, 110) we further observed a 
significant reduction in fasting plasma BG and total cholesterol, despite the fact that our study 
population was to a large extent healthy.  
Test-meals containing FOS promotes a trend toward lower glycaemic responses and peak 
insulin levels (111). Although not significant, we observed beneficial adjustments in insulin and 
glucagon levels after 2 weeks of FOS intake comparable to the results of Jackson et al. and Kaur & 
Gupta, respectively (112, 113).  
GIP and GLP-1 are major mediators in regulating postprandial insulin release and exhibit 
an insulin-like action on lipid metabolism (114, 115). In animal studies presenting the same 
glucometabolic modulations, these were attributed to the effects of inulin in increasing the 
secretion of GIP and GLP-1 from the caecum (116), and human studies affirm this observations 
(117) where incretins presumable are responsible for 70% of the insulin response during food 
intake in a healthy man (118). Also, FOS supplementation is linked to increased levels of 
pancreatic insulin content and to revert hepatic insulin resistance if the GLP-1 receptors are 
sufficiently functional in rats (116). 
A significant decrement in fasting plasma glucose concentration proceeded the FOS 
sequence, supporting the findings of Yamashita et al., 1984 (109), Hidaka et al. (119), and Kok et 
al. (116) (the latter using rat-models). Luo et al., postulated this to relay on a decreased basal 
hepatic glucose production in relation to the short-chain fatty acid propionate (120) highlighted by 
the effect of long-term oral propionate in healthy subjects to decrease fasting serum glucose and 
maximum insulin increment during glucose tolerance testing (121). 
Brun et al. (6) proposes that habitual activity level and diet may be important in the 
development of IRH. During moderate physical exercise glucagon and epinephrine are deficient 
and insulin secretion is stimulated, further amplify the risk of hypoglycaemia since frequent 
exercise increase insulin sensitivity. Taking this small sample size, their prominence to a healthy 
diet and high level of physical activity at baseline into consideration, the likelihood of modify 
glucometabolic parameters with fibre were expected to be limited. Furthermore were their habitual 
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numbers of daily meals reported to five, containing a high quantity of fibrous foodstuff, moreover 
decreasing the potential fibre effect of FOS.   
All the subjects enrolled in the present pilot intervention were invited to participate, 
regardless of contributing symptoms to hypoglycaemia. The fact that our appending criteria was 
relatively wide, gave a heterogeneous study population difficult to collate with the results of other 
studies. 17% reported daily manifestations and 58% sporadic symptoms admitted to 
hypoglycaemia at enrolment and we could not find an ameliorating effect of FOS. This may relate 
to the short study duration and the low number of participants, but perhaps mostly the lack of 
apparent symptoms as a requisition in participating. We also noticed a skewed reporting of 
symptoms with a higher rate in the beginning of the intervention, in spite of FOS intake. Apart 
from supplementing two daily meals with FOS, the subjects were not given any other dietary or 
habitually instructions. This concern, beside the choice of patients, background diet (gastro 
intestinal microflora condition) and physical activity, should be taken in future investigations of 
FOS’ ability in modulating glucose homeostasis. Besides, to accurately expose the relationship 
between low blood glucose and symptoms one should assess insulin and glucagon values 
throughout the OGTT, preferment using a hyperinsulinemic clamp.  
FOS appears to have the potential of modulating glucose oscillations and ameliorate an 
impaired incretin effect, malfunctions commonly seen in diabetics. In T2DM, GLP-1 and GIP 
disturbances accompanies inappropriately regulated glucagon secretion that leads towards 
chronically hyperglycaemia and increased risk of micro- and macrovascular complications (122). 
Fructo-oligosaccharides also promotes satiety (123) and should therefore be considered to 
comprise a new nutritional approach in T1DM and T2DM patients.  
This pilot study was of short duration and only included twelve participants without clinical 
post-study manifestation of symptoms, thereupon prone to selection biases. Although randomized, 
it was not double-blind and only enclosed one study centre. Due to shortcoming in time, we 
excluded a wash-out period between the treatment sequences, illustrating the possibility of FOS 
having a prolonged effect in the no-treatment weeks. Gibson et al. reported that for the population 
of bifidogenic bacteria to return to pre-supplementation numbers was determined by the dosage, 
with 1 day being necessary for each gram of inulin used per day (89)  
Although the benefits of fibre intake are unequivocal, current recommendations of intake 
and actual consumption disagree with 50% in the American population (124) as well as in the 





A reactive hypoglycaemic response following ingestion of glucose during an OGTT is prevalent 
and such a response could be modulated by dietary supplementation of fibre. Such a benefit is also 
likely in general life, in particular for those with sub-optimal fibre consumption and for those that 
reports some kind of hypoglycaemic symptoms. Because the intake of dietary fibre is significantly 
lower than the recommended amount for the population, the addition of oligofructose to a regular 
diet will benefit consumers by increasing overall fibre intake; and due to its unique composition 
generating higher viscosity than most polysaccharides, this functional fibre can also provide 
consumers added physiological benefits including, but not limited to increased glycaemic stability 
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7. TABLES  
 
Table 1. List of conditions associated with hypoglycaemia in adults without diabetes mellitus 
according to a healthy or ill appearance (modified from Harris, 1920 and Gama et al., 2003) 
(4, 147).   
Healthy appearing patient Ill appearing patient 
Endogenous hyperinsulinism (insulinoma) (20) and 
autoimmune insulin syndrome  (125) 
Hepatic or cardiac failure, sepsis (138)  
Functional β-cell disorders (nesidioblastosis) (126) Renal failure and concomitant use of 
trimetoprim (139) or quinidine (140)  
Non-islet cell tumour  (127) Inborn error of metabolism, i.e. Type I 
Glycogen storage disease (141)  
Noninsulinoma pancreatogenous hypoglycaemia 
syndrome (reduced glucagon and cortisol, growth 
hormone and/or epinephrine) (128, 37, 129); 
Congenital hypopituitarism (142) , growth 
hormone (143) or corticotrophin (144); 
deficiency 
Post gastric bypass hypoglycaemia (130) Addison’s disease (129) 
Intense exercise  (131) 
Ethanol (132) 
Galactosemia (145) or fructose-1,6-
diphosphatase deficiency (146)  
Undernutrition  (133) 
 
 
Drugs (insulin or insulin secretagogue, 
sulphonylureas (134), salicylates (135), quinine 
(136), haloperidol (137), β-adrenergic blocking 













Table 2. Characteristics of subjects (n =362) in a case-control study according to 
glucometabolic classification. 
  IRH T2DM IGT NGT 
n 45 (12.4%) 42 (11.6%) 71 (19.6%) 204 (56.4%) 
Anthropometric measurements  
Gender (F/M) 8 (17%)/38 (83%) 12 (29%)/30 (71%) 34 (48%)/37 (52%) 92(45%)/112 (55%) 
Age (years) 
(mean + SD) 68 + 10 73 + 7* 74 + 6*** 70 + 9 
BMI (kg/m2) 
(mean + SD)  24.7 + 3.3 25.3 + 3.8 25.3 + 3.7 25.0 + 3.5 
Waist circ. (cm) 
(mean + SD) 92 + 10 94 + 12 92 + 13 90 + 11 
Hip circ. (cm) 
(mean + SD) 101 + 6 102 + 8 101 + 8 101 + 9 
Cardiovascular complications n (%) 
CAD 5 (11.1%) 14 (33.3%)** 23 (32.4%)** 48 (23.5%)§ 
CVD 4 (8.9) 3 (7.1) 12 (16.9) 11 (5.4) 
Concomittant medications n (%) 
Betablockers 5 (11.1) 17 (40.8)*** 23 (32.4)** 60 (29.4)** 
RASB 5 (11.1) 7 (16.7) 10 (14.1) 16 (7.8) 
Aspirin 17 (37.8) 20 (47.6) 26 (36.6) 59 (28.9) 
Warfarin 1 (2.2) 11 (26.2)*** 7 (9.9) 10 (4.9) 
Statins 14 (31.1) 29 (69.0)*** 36 (50.7)* 73 (35.8) 
*, **, ***: Significant at the 0.05, 0.01, 0.001 level respectively vs. IRH-group, §: p=0.06. 





Table 3. Overall (n=362 or n=208) bivariate correlation (Pearsons r) between 
anthropometric, and HOMA-IR or fasting parameters of the inflammatory and IGF-system 
and glucose parameters of the OGTT. (r-values and level of significance indicated).   
  fcBG 1h-cBG 2h-cBG 
BMI (kg/m2) 0.212*** 0.167** 0.001 
Body weight (kg) 0.226*** 0.171*** -0.052 
Waist circum. (cm) 0.230*** 0.206*** 0.028 
Hip circum. (cm) 0.161** 0.126* 0.040 
HOMA-IR 0.348*** 0.232*** 0.156** 
White blood cells (109/L) 0.144** 0.189*** 0.122* 
CRP (mg/L)§ 0.172** 0.173** 0.274*** 
IL-10 (pg/mL) -0.096 -0.079 -0.049 
TGFB-1 (ng/mL) -0.101 -0.090 -0.125¤ 
TNFR-1(pg/mL)§ 0.152* 0.160* 0.269*** 
IGFBP-1(μg/mL)§ -0.102 -0.050 0.096 
IGFBP-3(μg/mL)§ -0.034 -0.083 -0.162* 
IGF-1(ng/mL)§ 0.057 0.003 -0.204** 
§: n = 208. For all other values n = 362.  
*, **, ***: Significant at the 0.05, 0.01, 0.001 level. ¤ Border line significant (p = 0.07). 
fcBG: fasting capillary blood glucose, BMI: body mass index, HOMA-IR: homeostasis model assessment of insulin 
resistance, CRP: c-reactive protein, IL-10: interleukin 10, TGFB-1: transforming growth factor β1,  TNFR-1: tumour 
necrosis factor-receptor, IGFBP-1: insulin-like growth factor binding protein, IGF-1: insulin-like growth factor. 
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Table 4. Characteristics of the GABI and ABAF study population according to 
glycometabolic classification. (Mean + SD). 
  IRH (N=45) T2DM (N=42) IGT (N=71) NGT (N=204) 
Fasting glycaemic parameters 
HbA1c (%) 5.7 + 0.4 6.0 + 0.6** 5.9 + 0.4 5.7 + 0.4 
fpBG (mmol/L) 5.2 + 0.5 6.2 + 0.9*** 5.4 + 0.5* 5.1 + 0.5 
Insulin (pmol/L) 81.0 + 32.8 113.8 + 77.8* 100.0 + 60.6 90.6 + 3.5 
HOMA-IR 3.5 + 1.5 6.2 + 4.5*** 4.6 + 2.9* 4.0 + 2.2 
2h OGTT results 
fcBG (mmol/L) 5.3 + 0.5 6.3 + 0.8*** 5.4 + 0.5 5.2 + 0.4* 
1-h cBG (mmol/L) 8.4 + 2.2 12.9 + 2.4*** 10.7 + 1.8*** 8.7 + 1.8 
2-h cBG (mmol/L) 4.4 + 0.9 10.8 + 3.2*** 8.8 + 0.8*** 6.5 + 0.7*** 
Lipid parameters 
TG (mmol/L) 1.0 + 0.5 1.4 + 0.8* 1.3 + 0.9 1.2 + 0.7 
Tot. chol. (mmol/L) 5.2 + 1.0 4.7 + 1.0* 5.2 + 1.3 5.3 + 1.1 
HDL (mmol/L) 1.6 + 0.4 1.5 + 0.6 1.7 + 0.5 1.7 + 0.5 
LDL (mmol/L)  3.1 + 0.9 2.5 + 0.9** 3.0 + 1.1 3.1 + 1.0 
Parameters of inflammation and the IGF-system 
White blood cells 
(109/L) 6.5 + 1.6 6.8 + 2.1 6.8 + 1.8 6.2 + 1.6 
IL-10 (pg/mL) 0.6 + 0.1 1.1 + 1.2* 0.7 + 0.4 1.8 + 6.5 
CRP (mg/L) 2.3 + 2.7 5.6 + 6.6* 4.6 + 5.2* 3.1 + 4.2 
TNFR-1 (pg/mL) 779.2 + 200.4 1196.6 + 675.9** 1014.1 + 421.4** 908.9 + 355.2 
IGFBP-1 (μg/mL) 44.9 + 30.0 50.5 + 42.0 47.4 + 36.5 50.7 + 37.0 
IGFBP-3 (μg/mL) 1.7 + 0.4 1.5 + 0.5 1.5 + 0.4 1.5 + 0.4 
TGFB-1 (ng/mL) 7.5 + 4.4 5.3 + 2.1* 6.4 + 3.4 6.7 + 3.6 
IGF-1 (ng/mL) 80.9 + 22.4 64.6 + 26.2* 67.2 + 25.8* 71.8 + 29.3 
*, **, ***: Significant at the 0.05, 0.01, 0.001 level respectively vs. IRH-group. 
HbA1c: Glycosylated haemoglobin A1c, fpBG: fasting plasma blood glucose, HOMA-IR: homeostasis model of inulin 
resistance, fcBG: fasting capillary blood glucose, TG: triglycerides Tot. chol.: total cholesterol, HDL/LDL: high/low 
density lipoprotein, IL-10: interleukin 10, CRP: c-reactive protein, TNFR-1: tumour necrosis factor-receptor 1  
IGFBP: insulin-like growth factor binding protein, TGFB-1: transforming growth factor β1, IGF-1: insulin-like 











Table 5. General characteristics and observations of IRH study participants at baseline. 
 Mean + SD Min - max 
Age (years) 56.3 + 8.3 41 – 75 
Weight (kg) 76.5 54.9 – 95.5 
BMI (kg/m2) 25.0 + 2.9 20.0 – 29.1 
Systolic blood pressure (mmHg) 123.1 + 21.7 90.5 – 167.5 
Diastolic blood pressure (mmHg) 78.5 + 12.7 63.5 – 103.0 
Number of meals 4.7 + 0.9 3 – 6  
Leisure time physical activity (min/week)* 347.1 + 144.5 70 – 540 
Nr. of daily meals containing fibre**  2.5 + 1.1 1 – 4 
TV/reading (min/week) 1440.0 + 968.1 525 – 4200 
Smokers (n (%)) 1 (8.3)   
Coronary artery disease (n (%)) 2 (16.7)  
Cerebrovascular disease (n (%)) 1 (8.3)  
Beta blocker (n (%)) 1 (8.3)  
Angiotensin receptor blocker (n (%)) 2 (16.7)  
Aspirin (n (%)) 3 (25)  
Warfarin (n) 0  
Statin (n (%)) 3 (25)  
*All participants performed > 4 work out sessions/week 
** Selected fibre containing groceries accessed by questionnaire 




Table 6. Laboratory parameters of IRH study participants at baseline (fasting). 
 Total Range 
Leukocytes (109/L) 5.1 + 0.8 3.9 – 6.7 
CRP (mg/L) 1.0 + 0.9 0.3 – 3.4 
ASAT (U/L) 25.6 + 6.7 18 – 40 
ALAT (U/L) 25.3 + 14.7 4 – 57 
Cholesterol (mmol/L) 5.3 + 1.1 3.6 – 7.2 
TG (mmol/L) 1.0 + 0.5 0.4 – 2.2 
HDL (mmol/L) 1.8 + 0.6 1.0 – 2.9 
LDL (mmol/L) 3.0 + 0.9 1.6 – 4.1 
Glucose (mmol/L) 5.4 + 0.6 4.4 – 6.1 
HbA1c (%) 5.8 + 0.3 5.4 – 6.5 
Insulin (pmol/L) 26.7 + 15.7 15 – 72 
Glucagon (pmol/L) 17.6 + 3.6 11.4 – 22.3 
Insulin/Glucagon ratio 1.4 + 0.8 0.9 – 3.5 
HOMA-IR*  1.0 + 0.7 0.6 – 2.9 
CRP: c-reactive protein, ASAT: aspartate aminotransferase, ALAT: alanine amino transferase, TG: triglycerides, 
HDL:  high density lipoprotein, LDL: low density lipoprotein, HbA1c: Glycosylated haemoglobin A1c, HOMA-IR: 
homeostasis model of inulin resistance. 
* [fasting plasma insulin].[fasting plasma glucose] 
                                      135 
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Table 7. Sequence-end results for the 4h-OGTT of each 2-week cycle. (Mean values 
indicated).  





n = 12 
Statistical analysis (mean 
diff/t-value/p-value) 
Glucose levels 
Fasting glucose (mmol/L) 5.2 (0.4) 5.5 (0.6) -0.3/-1.6/0.15 
Glu_30 min (mmol/L) (SD) 10.3 (2.0) 10.5 (1.8) -0.2/-0.3/0.77 
Glu_60 min (mmol/L) (SD) 9.3 (2.1) 10.2 (2.3) -0.9/-1.3/0.24 
Glu_90 min (mmol/L) (SD) 7.2 (1.7) 7.9 (1.7) -0.7/-1.3/0.20 
Glu_120 min (mmol/L) (SD) 5.7 (1.8) 5.8 (1.7) -0.05/-0.09/0.93 
Glu_150 min (mmol/L) (SD) 4.5 (1.4) 4.7 (1.3) -0.2/-0.7/0.48 
Glu_180 min (mmol/L) (SD) 4.4 (0.6) 4.0 (0.8) 0.4/2.6/0.03 
Glu_210 min (mmol/L) (SD) 4.4 (0.3) 4.1 (0.3) 0.3/2.0/0.07 
Glu_240 min (mmol/L) (SD) 4.5 (0.3) 4.4 (0.4) 0.2/0.8/0.43 
AUC                                                                                                           p-value 
0-30 (mmol/L.min) 233 (32.4) 240 (32.3) 0.56 
30-60 (mmol/L.min) 295 (50.7) 310 (58.5) 0.39 
60-90 (mmol/L.min) 248 (53.2) 271 (52.9) 0.21 
90-120 (mmol/L.min) 194 (46.2) 205 (43.3) 0.39 
120-150 (mmol/L.min) 153 (42.5) 157 (40.9) 0.72 
150-180 (mmol/L.min) 133 (28.7) 130 (29.9) 0.48 
180-210 (mmol/L.min) 132 (9.9) 121 (16.1) 0.02 
210-240 (mmol/L.min) 135 (7.0) 128 (9.4) 0.11 
Total (mmol/L.min) 1522 (62.2) 1561.3 (72.5) 0.28 
Parameters of the OGTT curve                                                                  p-value 
Shape-index* 1.5 (1.6) 2.1 (1.7) 0.35 
Shape of the OGTT curve                                                                Chi-Squared test p-value  
 
monophasic 3 0 0.08  
biphasic 9 12 0.5 
cBG counts     
< 3.9 mmol/L 11 21 0.04 
*Glu_90 min – Glu_120 min 
AUC: area under curve 
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Table 8. Sequence-end results for self monitoring of blood glucose. (Mean values indicated). 
Mean values (SD)  
Sequence A 
(FOS) 
n = 12 
Sequence B
(no FOS) 
n = 12 
Statistical analysis (mean 
diff./t-value/p-value) 
8a.m. (mmol/L (SD)) 5.3 (0.4) 5.7 (1.2) -0.4/-1.3/0.22  
10a.m. (mmol/L (SD)) 5.3 (0.8) 6.4 (2.1)  -1.1/-1.2/0.31 
12a.m. (mmol/L (SD)) 5.8 (1.6) 6.8 (1.7)  -1.0/-1.0/0.34 
2a.m. (mmol/L (SD)) 5.9 (1.2) 5.4 (1.0)  0.6/0.6/0.58 
5a.m. (mmol/L (SD)) 5.4 (1.0) 6.1 (1.5)  -0.7/-1.3/0.23 
7.30p.m. (mmol/L (SD)) 6.2 (1.2) 5.1 (0.9)  1.2/2.3/0.05 
10.30p.m. (mmol/L (SD)) 6.4 (1.2) 6.1 (0.4) 0.3/0.8/0.44 
AUC_glucose (mmol/L.min)  84.1 (3.4) 85.4 (2.2) p = 0.75  
AUC: area under curve 
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Table 9. Sequence-end results of fasting glucometabolic parameters and anthropometric 




n = 12 
Sequence B 
(no FOS) 
n = 12 
Statistical analysis  
(mean diff./p-value) 
HbA1c (%) 5.9 (0.2) 5.9 (0.2) -0.5/0.59 
Glucose (mmol/L) 5.1 (0.5) 5.4 (0.6) -2.0/0.05 
Insulin (pmol/L) 23.8 (10.8) 25.1 (11.8) -0.9/0.35 
Glucagon (pmol/L) 17.0 (4.4) 16.6 (3.4) -0.36/0.72 
HOMA-IR (%) 1.0 (0.5) 1.2 (0.7) -1.4/0.16 
Insulin-Glucagon ratio 1.4 (0.6) 1.5 (0.6) -0.7/0.48 
Total cholesterol (mmol/l) 4.9 (1.1) 5.3 (1.1) -0.2/0.04 
LDL cholesterol (mmol/l) 2.7 (0.7) 3.0 (0.9) -1.1/0.25 
HDL cholesterol (mmol/l) 1.7 (0.6) 1.9 (0.7) -2.6/0.01 
Triglycerides (mmol/l) 1.0 (0.4) 1.0 (0.7) -1.0/0.31 
CRP (mg/L) 1.6 (1.7) 0.9 (0.9) -2.0/0.04 
White blood cells (10^9/L) 4.8 (1.1) 5.1 (1.1) -0.9/0.35 
Abbreviations: BP – blood pressure, HOMA-IR:  homeostasis model of inulin resistance 







































Figure 4. Glucose levels during an OGTT in the different glucometabolic groups (mean ± 
SD). 














































fasting 30 60 90 120 150 180 210 240


























































































































































































































































































































































































































































































































Figure 6(a-l). Individual 4h OGTT glycaemic profiles in each 2-weeks intervention sequence. 
  
  a)            b)        c)    
                                
d)             e)               f)  
             
               
 g)            h)        i)    
    
           
j)            k)        l)    
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Figure 7. Proportions of subjects that during 120 - 240 minutes had cBG < 3.9 mmol/L in the 
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Food plan app. 1800 kcal 
 
Breakfast 
1 fruit or 1dl orange juice 
2 slices whole kernel bread or 4dl oatmeal porridge with water or 1dl müesli 
1 teaspoon (ts) soft margarine or 2ts diet margarine or 10 pieces unsalted nuts 
2 slices diet cheese  
1 glass of skimmed milk 
Vegetables as much as you like 
Coffee/tea without sugar 
 
Lunch 
2 slices whole kernel bread 
1ts soft margarine or 2ts diet margarine 
App. 50g fish or meat low in fat  
Vegetables as much as you like/salad 
1 glass of skimmed milk or 1 portion of yoghurt (Yoplait 0.1%) 
1 fruit 
Coffee/tea without sugar 
 
Snack 
1 bagel or 2 crispbread 
1ts soft margarine or 2ts diet margarine 
2 slices diet cheese  





App. 120g low fat meat or any kind of fish or poultry without skin 
3 boiled potatoes or 2dl boiled rice/pasta/beans 
3/4dl dressing 
1 tablespoon (TS) olive/raps oil 
1 portion boiled vegetables 
1 portion salad 
1 TS dressing or vinaigrette 
Water/diet soda 
Dessert: 1-2dl fresh/frozen berries or 1 fruit 
 
Supper 
1 slice whole kernel bread or 2 crispbread 
1ts soft margarine or 2ts diet margarine 
1 slice diet cheese or diet melted cheese 
















Food plan 2100-2200 kcal 
 
Breakfast 
1 fruit  
1.5dl müesli with fruits, nuts and 2dl skimmed milk 
or 
2 slices whole kernel bread  
Soft margarine, low fat meat, raw vegetables 
1 glass of skimmed milk 
Coffee/tea without sugar 
 
Lunch 
2 slices whole kernel bread 
2ts soft margarine  
Cold cuts of fish or meat low in fat  
Vegetables as much as you like 
1 glass of skimmed milk  
1 fruit 









App. 150g low fat meat or any kind of fish or poultry without skin 
3 boiled potatoes or 2dl boiled rice/pasta/beans 
1dl low fat dressing 
1TS olive/raps oil 
1 portion boiled vegetables 
1 portion salad 
1TS vinaigrette 
Water/diet soda 
Dessert: 1-2dl fresh/frozen berries  
 
Supper 
2 slices whole kernel bread  
1ts soft margarine  
2 slices diet cheese  






























2) Har du vært innlagt på sykehus etter 01.05.2008?  
(Svar Ja/Nei i grå boks)  
 
 
















Vennligst spesifiser hvilke symptomer du har: (Sett kryss for å bekrefte, 
flere kryss mulig) 
a) Svimmelhet   
b) Skjelving   
c) Hodepine   
d) Svette/kaldsvette   
e) Irritabilitet   
f) Sult   
g) Søvnig på dagtid   
h) Blekhet   
i) Hjertebank   
j) 
Konsentrasjonsvansker   
k) Annet:   
 
a) Aldri  (→ gå til spm. 5)   
b) 3 eller færre ganger pr 
måned 
  
c) Ukentlig   
d) 3 eller færre ganger pr 
uke 
  
e) Daglig   
f) Flere ganger daglig   
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4) Har du noen gang tatt kontakt med lege i forbindelse med 
symptomer på lavt blodsukker? (Ja/Nei) 
 
5) Har du i løpet av den siste måneden hatt følgende plager? 
                                                    Mye    Litt 
                    plaget  plaget   Nei 
a) Luft i magen                    
b) Rumling i magen            
c) Forstoppelse        
d) Diaré        
e) Svimmelhet       
f) Hodepine       
g) Aggressivitet       
h) Skjelvinger       
i) Sult mellom måltider       
j) Smerter generelt       
 
 
6) Hvor mange hovedmåltider spiser du hver dag? (Sett strek under 
riktig svaralternativ) 
 
1        2       3       4       5       6       7 
 
7) Hvor mange delmåltider/snacks spiser du hver dag? (Sett strek 
under riktig svaralternativ) 
 
1        2       3       4       5       6       7 
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8) Røyker du? (Ja/Nei)  
Hvis JA, hvor mange år har du røkt?______________ 
Hvor mange sigaretter har du røkt daglig i gjennomsnitt?  
 
Hvis NEI, har du tidligere røkt daglig? (Ja/Nei)   
 
Hvor mange år er det siden du sluttet: _____ 
Hvor mange år til sammen røykte du daglig: _____ 
Hvor mange sigaretter røykte du daglig: _____ 
 
 
9) Drikker du alkohol? (Ja/Nei) 
 
Hvis JA, hvor mange glass drikker du vanligvis i løpet av 2 uker: 
 
ØL: ___  VIN: ___    BRENNEVIN: ___ 
 
 
10) Arbeidsforhold (kryss av for nåværende situasjon): 
I full jobb: ___ 
Deltidsjobb (angi %): ___ 












12) Hva heter din fastlege? __________________________________ 
 
13) Har du noen form for matvareallergi? (Ja/Nei)  
 




14) Vektlegger du et sunt kosthold? (Sett strek under riktig 
svaralternativ) 
 
Svært mye         mye              middels               lite                   svært lite 
 
 
15) Hvor mye veide du for 1 år siden? (Angi antall kg):____________ 
 




17) Hvor mange kopper te (ca 2 dl) drikker du hver dag? (Angi 
antall):____________ 
 
18) Hvor ofte spiser du følgende matvarer?  
 Daglig Ukentlig Månedlig 
Sjelden/ 
aldri 
a) Linser/Bønner         
b) 
Fullkornsbrød/knekkebrød         
c) Porsjon av 400 g 
grønnsaker         
d) Frukt         
e) 
Frokostblanding/havregryn         
f) Nøtter         
 
19) Hvordan vurderer du din helse? (Sett strek under riktig 
svaralternativ) 
 
Meget god          God         Verken/eller         Dårlig         Svært dårlig 
  
 
20) Medisiner; vennligst fyll ut navnet på, styrken på, og hvor ofte du 
tar medisiner nedenfor.  
 
 1. ____________________________________________________ 
 
 2. ____________________________________________________ 
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 3. ____________________________________________________ 
 
 4. ____________________________________________________ 
 
 5. ____________________________________________________ 
 6. ____________________________________________________ 
 
 7. ____________________________________________________ 
 
 8. ____________________________________________________ 
 
 9. ____________________________________________________ 
 
 10. ___________________________________________________ 
 
21) Kosttilskudd; (f.eks. omega-3, multivitamin). Vennligst fyll ut navnet 
på, og antall tabletter nedenfor.  
           
1.____________________________________________________ 
 
 2. ____________________________________________________ 
 
 3. ____________________________________________________ 
 
 4. ____________________________________________________ 
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 5. ____________________________________________________ 
 
 6. ____________________________________________________ 
 
 7. ____________________________________________________ 









24) Har du drevet noen former for mosjonsrelaterte aktiviteter de siste 
syv dager? (Ja/Nei)  
 
25) Hvis ja, hva gjorde du, hvor mange ganger og hvor lenge drev du 
med denne (disse) aktivitetene? 
     Intensitet 
 
Antall ganger 
(siste 7 dager) Minutter totalt    Lett Moderat   Tungt 
a) Spasertur (rolig 
gange)            
b) Turgåing (rask 
gange)           
c) Bowling           
d) Sykling           
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e) Gymnastikk/trim           
f) Svømming           
g) Dans            
h) Styrketrening           
i) Anstrengende 
husarbeid           
j) Annet:________           
26) Gjør du disse aktivitetene regelmessig? (Ja/Nei)  
 




gang   1 gang 2 ganger 
3-4 
ganger 
   > 4 
ganger  
           
            
            
      
      
27) Bruker du trapper fremfor heis/rulletrapp? 
             Ja   
             Nei  
             Av og til 
 
28) Dersom du er i arbeid, har du en stillesittende jobb? 
(Ja/Nei)  
  
Hvis NEI, hvor mange timer beveger du deg hver dag på jobb?  
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     (Angi antall):____________ 
 
29) Hvor mye tid bruker du gjennomsnittlig pr dag på disse 




Man - Fre 
Minutter helg/ 
fridager 
TV     
Lese     
 
